Exchange: NYSE·Updated 07:40 PM EDT

NVS News

News
all
press releases
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
More News
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVSPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating...
PR Newswire
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
FDA approves Novartis's Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hivesread more...
Benzinga
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Zacks
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
Stocktwits
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVSPR NewswireNEW YORK, Oct. 1, 2026NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating...
PR Newswire
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Stocktwits
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Zacks

Advertisement|Remove ads.